Today: 21 May 2026
Ondas (ONDS) stock on watch after $1B offering priced above market; week ahead in focus
11 January 2026
2 mins read

Ondas (ONDS) stock on watch after $1B offering priced above market; week ahead in focus

NEW YORK, January 11, 2026, 05:52 EST — Market closed

  • Ondas shares fell 2.3% Friday, despite the company pricing a $1 billion stock-and-warrant offering above market value.
  • The deal features pre-funded warrants alongside long-dated warrants that can be exercised at $28 per share, creating a possible overhang.
  • Investors are now focused on Monday’s expected closing, followed by management appearances on Jan. 14 and Jan. 16.

Ondas Holdings Inc shares slipped 2.3% to close at $13.69 on Friday after the company announced a $1 billion registered direct offering, pricing stock and warrants at $16.45 per package. That price marks roughly a 17.5% premium to the stock’s Jan. 8 closing level. The Nasdaq-listed stock traded in a range from $15.10 down to $13.59, with volume hitting about 114 million shares.

The timing is crucial. This sizable financing, loaded with optional shares, arrives right when traders are trying to separate Ondas’s story from its cash and contracts.

Investors face a stark trade-off: new capital to fuel acquisitions and growth, weighed against the risk of dilution and a warrant-heavy setup that could limit upside rallies.

Ondas announced plans to sell 19,000,000 shares along with pre-funded warrants convertible into up to 41,790,274 shares instead of common stock. Every common stock equivalent includes a warrant allowing the purchase of two additional shares, totaling 121,580,548 warrant shares, all priced at an exercise price of $28.

The company anticipates closing the offering around January 12, pending usual conditions. It aims to deploy the funds toward corporate development and strategic growth, covering acquisitions, joint ventures, and investments. Oppenheimer is the lead placement agent, supported by co-placement agents Stifel, Needham, Lake Street, Northland, Ladenburg Thalmann, H.C. Wainwright, and Maxim.

A prospectus supplement estimated net proceeds around $959 million, after deducting placement-agent fees and offering costs, not counting potential cash from warrant exercises. The filing noted the warrants likely won’t have an active trading market, and Ondas doesn’t plan to list them.

A registered direct offering involves selling securities straight to investors through an SEC-registered process, skipping the usual public roadshow. Pre-funded warrants act like a stock stand-in: investors pay nearly the full price upfront, then exercise them later for a small fee, often to keep ownership percentages in check.

Ondas revealed preliminary, unaudited financials for Sentry CS Ltd in a separate filing on Friday. The company, acquired last November, reported sales near $11.3 million for 2024 and $11.0 million in the first half of 2025. It also recorded net losses of roughly $13.5 million and $4.5 million for those periods, according to the filing.

Ondas has positioned itself as a defense-and-security tech platform following several recent deals. Chairman and CEO Eric Brock said earlier this month, “While Ondas Holdings reflected an earlier phase of our development, today, we operate as a scaled, global defense and security technology platform.” Ondas Holdings Inc.

The next key dates are coming fast: Ondas is set to appear at the Needham Growth Conference on Jan. 14, then it holds an OAS investor day two days later, on Jan. 16. Traders will zero in on guidance, product rollout speed, and how the company plans to allocate capital.

The downside risk is spelled out in the term sheet. New shares plus warrant-linked shares could dilute current holders. If the stock fails to rise above $28, those warrants might never be exercised for cash, turning a large slice of “potential” proceeds into nothing more than a paper promise.

Stock Market Today

  • Sudarshan Colorants India's Earnings Show Potential Despite Profit Dip
    May 20, 2026, 8:53 PM EDT. Sudarshan Colorants India Limited (NSE:SUDARCOLOR) reported weaker profits last quarter, impacted by ₹50 million in unusual expenses that are unlikely to recur, suggesting potential profit rebound. The company's earnings per share (EPS) are growing strongly, indicating solid underlying business performance. Investors should consider balance sheet strength and monitor two identified warning signals, one considered significant. While profit was soft this time, analysts view Sudarshan Colorants' earnings outlook as cautiously optimistic, citing quality income statement elements and possible earnings improvements in the next quarter.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results
Previous Story

BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Next Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

Go toTop